Keyword Search
Legend:
CC = Baltimore Convention Center, H = Hilton Baltimore
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: phase II returned 14 record(s)
|
|
Sunday, 07/30/2017
|
Bayesian Methods for Analysis of Biosimilar Phase III Trials
Robert Weiss, UCLA Fielding School of Public Health; Xiaomao Simon Xia, University of Missouri; Nan Zhang, Amgen Inc; Hui Wang, Amgen Inc; Eric Chi, Amgen, Inc.
2:35 PM
|
Investigation on Combining Phase II Proof-Of-Concept Trial with Dose Finding Trial
Yutao Liu, Columbia University; Qiqi Deng, Boehringer Ingelheim Pharmaceuticals, Inc.; Ken Cheung, Deptment of Biostatistics, Columbia University
4:05 PM
|
|
Monday, 07/31/2017
|
Two-Stage Design for Phase II Cancer Clinical Trials with Multiple Endpoints
Hui Gu, Rutgers University; Yong Lin, Rutgers; Weichung Joe Shih, Rutgers School of Public Health; Yaqun Wang, Rutgers; Kejian Liu, Celgene
|
Sequential Clinical Trial Design for Basket Phase II
Shilan Li; Hongbin Fang, Georgetown University; Ming T Tan, Georgetown University
|
Phase II Trials and the Use of Registry Controls
Ruta Brazauskas, Institute for Health & Society-Medical College of Wisconsin; Brent Logan, Institute for Health & Society-Medical College of Wisconsin; Raphael Fraser, Institute for Health & Society-Medical College of Wisconsin
8:50 AM
|
|
Tuesday, 08/01/2017
|
A Two-Stage Design for Phase III Trials with Population Selection
Wen Li, Merck & Co. Inc.
8:50 AM
|
Earning Regulatory Approval for a Phase II/III Design: a Case Study from Start to Finish
Adam Hamm, Cytel, Inc.
9:20 AM
|
Adaptive Designs in Phase II Basket Clinical Trials
Kristen Cunanan; Alexia Iasonos, Memorial Sloan Kettering Sloan Cancer Center; Ronglai Shen, Memorial Sloan Kettering Cancer Center; Colin Begg, Memorial Sloan Kettering Cancer Center; Mithat Gonen, Memorial Sloan Kettering Cancer Center
9:35 AM
|
A New Distribution-free Phase II Shewhart Control Chart for Location
Yuhui Yao, University of Alabama; Subhabrata Chakraborti, University of Alabama
11:50 AM
|
|
Wednesday, 08/02/2017
|
BOP2: Bayesian Optimal Designs for Phase II Clinical Trials with Simple and Complex Endpoints
Heng Zhou, MD Anderson Cancer Center; Ying Yuan, M.D. Anderson Cancer Center
8:35 AM
|
Bayesian Design for Interim Analysis
Dung-Tsa Chen, Moffitt Cancer Center
9:20 AM
|
A Practical Application of Multiple Imputation (MI) in a Double Blinded Randomized Phase III Study in Spinal Muscular Atrophy
Peng Sun, Biogen; Richard Foster, Biogen; Guochen Song, Biogen; John Zhong, Biogen
11:05 AM
|
Missing Data - How Much Is Too Much ?
Lilianne (Lee-Lian) Kim, Janssen Pharmaceuticals R&D; Kim Hung Lo, Janssen R&D, LLC
11:20 AM
|
|
|
